TY - JOUR
T1 - Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
AU - COVID-19 and Cancer Consortium
AU - Rubinstein, Samuel M.
AU - Bhutani, Divaya
AU - Lynch, Ryan C.
AU - Hsu, Chih Yuan
AU - Shyr, Yu
AU - Advani, Shailesh
AU - Mesa, Ruben A.
AU - Mishra, Sanjay
AU - Mundt, Daniel P.
AU - Shah, Dimpy P.
AU - Sica, R. Alejandro
AU - Stockerl-Goldstein, Keith E.
AU - Stratton, Catherine
AU - Weiss, Matthias
AU - Beeghly-Fadiel, Alicia
AU - Accordino, Melissa
AU - Assouline, Sarit E.
AU - Awosika, Joy
AU - Bakouny, Ziad
AU - Bashir, Babar
AU - Berg, Stephanie
AU - Bilen, Mehmet Asim
AU - Castellano, Cecilia A.
AU - Cogan, Jacob C.
AU - Devendra, K. C.
AU - Friese, Christopher R.
AU - Gupta, Shilpa
AU - Hausrath, Daniel
AU - Hwang, Clara
AU - Johnson, Nathalie A.
AU - Joshi, Monika
AU - Kasi, Anup
AU - Klein, Elizabeth J.
AU - Koshkin, Vadim S.
AU - Kuderer, Nicole M.
AU - Kwon, Daniel H.
AU - Labaki, Chris
AU - Latif, Tahir
AU - Lau, Eric
AU - Li, Xuanyi
AU - Lyman, Gary H.
AU - McKay, Rana R.
AU - Nagaraj, Gayathri
AU - Nizam, Amanda
AU - Nonato, Taylor K.
AU - Olszewski, Adam J.
AU - Polimera, Hyma V.
AU - Portuguese, Andrew J.
AU - Puc, Matthew M.
AU - Razavi, Pedram
AU - Rosovski, Rachel
AU - Schmidt, Andrew
AU - Shah, Sumit A.
AU - Shastri, Aditi
AU - Su, Christopher
AU - Torka, Pallawi
AU - Wise-Draper, Trisha M.
AU - Zubiri, Leyre
AU - Warner, Jeremy L.
AU - Thompson, Michael A.
AU - Choueiri, Toni K.
AU - Duma, Narjust
AU - Farmakiotis, Dimitrios
AU - Grivas, Petros
AU - Lopes, Gilberto de Lima
AU - Painter, Corrie A.
AU - Peters, Solange
AU - Rini, Brian I.
AU - Shah, Dimpy
AU - Thompson, Michael A.
AU - Warner, Jeremy L.
N1 - Publisher Copyright:
© 2022 American Association for Cancer Research.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non–B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non–recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19.
AB - Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non–B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non–recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85131004413&partnerID=8YFLogxK
U2 - 10.1158/2643-3230.BCD-22-0013
DO - 10.1158/2643-3230.BCD-22-0013
M3 - Article
C2 - 35262738
AN - SCOPUS:85131004413
SN - 2643-3230
VL - 3
SP - 181
EP - 193
JO - Blood cancer discovery
JF - Blood cancer discovery
IS - 3
ER -